Story perspectives

20% of GLP-1 users report hair shedding

By Drooid · Sep 28, 2026, 12:00 AM UTC · How we work

Summary

Story summary

Patients in the U.S., U.K., and EU using GLP-1 drugs report hair loss.
About 20 million tirzepatide or semaglutide users report hair shedding, a 20 % rate.
Hair loss typically starts within the first year, peaks before month 12, then declines.
Telogen effluvium is the most common form, affecting women in nearly 90 % of cases.

1 of 1

Story summary

Patients in the U.S., U.K., and EU using GLP-1 drugs report hair loss.
About 20 million tirzepatide or semaglutide users report hair shedding, a 20 % rate.
Hair loss typically starts within the first year, peaks before month 12, then declines.
Telogen effluvium is the most common form, affecting women in nearly 90 % of cases.